Department of Surgery, Stanford University, CA. Electronic address: https://twitter.com/DrJRB.
University of Oxford, UK. Electronic address: https://twitter.com/OmairShariq.
Surgery. 2022 Aug;172(2):723-728. doi: 10.1016/j.surg.2022.04.011. Epub 2022 May 14.
The optimal surgical management of pancreatic neuroendocrine tumors in patients with multiple endocrine neoplasia type 1 is controversial. This study sought to compare clinicopathologic characteristics and outcomes of multiple endocrine neoplasia type 1-associated and sporadic pancreatic neuroendocrine tumors from a large multi-national database.
A multi-institutional, international database of patients with surgically resected pancreatic neuroendocrine tumors was analyzed. The cohort was divided into 2 groups: those with multiple endocrine neoplasia type 1 versus those with sporadic disease. Clinicopathologic comparisons were made. Overall and disease-free survival were analyzed. Propensity score matching was used to reduce bias.
Of 651 patients included, 45 (6.9%) had multiple endocrine neoplasia type 1 and 606 sporadic pancreatic neuroendocrine tumors. Multiple endocrine neoplasia type 1-associated pancreatic neuroendocrine tumors were more common in younger patients and associated with multifocal disease at the time of surgery and higher T-stage. Lymph node involvement and the presence of metastasis were similar. Total pancreatectomy rate was 5-fold higher in the multiple endocrine neoplasia type 1 cohort. Median survival did not differ (disease-free survival 126 months multiple endocrine neoplasia type 1 vs 198 months sporadic, P > .5). After matching, survival remained similar (overall survival not reached in either cohort, disease-free survival 126 months multiple endocrine neoplasia type 1 vs 198 months sporadic, P > .5). Equivalence in overall survival and disease-free survival persisted even when patients who underwent subtotal and total pancreatectomy were excluded.
Multiple endocrine neoplasia type 1-associated pancreatic neuroendocrine tumors are more common in younger patients and are associated with multifocality and higher T-stage. Survival for patients with multiple endocrine neoplasia type 1-associated pancreatic neuroendocrine tumors is comparable to those with sporadic pancreatic neuroendocrine tumors, even in the absence of radical pancreatectomy. Consideration should be given to parenchymal-sparing surgery to preserve pancreatic function.
在多发性内分泌肿瘤 1 型(MEN1)患者中,胰腺神经内分泌肿瘤的最佳手术治疗存在争议。本研究旨在通过一个大型多国家数据库比较 MEN1 相关和散发性胰腺神经内分泌肿瘤的临床病理特征和结局。
分析了一个多机构、国际的胰腺神经内分泌肿瘤手术切除患者数据库。该队列分为 2 组:MEN1 组和散发性疾病组。进行了临床病理比较。分析了总生存期和无病生存期。采用倾向评分匹配减少偏倚。
在纳入的 651 例患者中,45 例(6.9%)患有 MEN1,606 例为散发性胰腺神经内分泌肿瘤。MEN1 相关胰腺神经内分泌肿瘤在较年轻的患者中更为常见,且在手术时与多灶性疾病相关,并具有更高的 T 分期。淋巴结受累和转移的存在相似。MEN1 组全胰切除术的比例高 5 倍。无病生存期(MEN1 为 126 个月,散发性为 198 个月,P >.5),中位生存时间无差异。匹配后,生存情况仍相似(MEN1 组总生存期未达到,散发性为 126 个月,P >.5)。即使排除接受次全和全胰切除术的患者,总体生存和无病生存的等效性仍然存在。
MEN1 相关胰腺神经内分泌肿瘤在较年轻的患者中更为常见,与多灶性和更高的 T 分期相关。MEN1 相关胰腺神经内分泌肿瘤患者的生存与散发性胰腺神经内分泌肿瘤患者相当,即使没有根治性胰切除术。应考虑保留胰腺功能的实质保留手术。